Breaking News
Investing Pro 0
🚨 NDVA surged 43%. This AI Chipmaker Could Be Next See Analysis
Close

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,360.00 +14.00    +1.04%
02/06 - Closed. Currency in MXN ( Disclaimer )
  • Volume: 5
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1,360.00 - 1,360.00
Type:  Equity
Market:  Mexico
ISIN:  US3755581036 
S/N:  375558103
Gilead 1,360.00 +14.00 +1.04%

GILD Balance Sheet

 
Assess the latest Gilead balance sheet. Review the company's financial position, assess their current assets, liabilities and shareholder equity across the most recent periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/03
2022
31/12
2022
30/09
2022
30/06
Total Current Assets 13456 14443 13554 13175
Cash and Short Term Investments 6518 7144 6238 6140
Cash - - - -
Cash & Equivalents 4936 5412 4699 4739
Short Term Investments 1582 1732 1539 1401
Total Receivables, Net 4162 4777 4354 4118
Accounts Receivables - Trade, Net 4162 4777 4354 4118
Total Inventory 1576 1507 1463 1494
Prepaid Expenses 1169 955 1274 1296
Other Current Assets, Total 31 60 225 127
Total Assets 61876 63171 62557 62870
Property/Plant/Equipment, Total - Net 5479 5980 5349 5299
Property/Plant/Equipment, Total - Gross - 8166 - -
Accumulated Depreciation, Total - -2186 - -
Goodwill, Net 8314 8314 8314 8314
Intangibles, Net 28348 28894 29440 29885
Long Term Investments 2642 2611 2596 2836
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 3637 2929 3304 3361
Other Assets, Total -973 -1478 -1127 -1096
Total Current Liabilities 10528 11237 10423 9220
Accounts Payable 627 905 614 565
Payable/Accrued - - - -
Accrued Expenses 4184 6534 6245 6349
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 2283 2384 2270 1021
Other Current liabilities, Total 3434 1414 1294 1285
Total Liabilities 40937 41962 41500 42655
Total Long Term Debt 22956 22957 22953 25195
Long Term Debt 22956 22957 22953 25195
Capital Lease Obligations - - - -
Deferred Income Tax 2401 2673 3036 3364
Minority Interest -58 -31 -24 -21
Other Liabilities, Total 5110 5126 5112 4897
Total Equity 20939 21209 21057 20215
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 1 1 1 1
Additional Paid-In Capital 5793 5550 5226 5031
Retained Earnings (Accumulated Deficit) 15223 15687 15756 15117
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -78 -29 74 66
Total Liabilities & Shareholders' Equity 61876 63171 62557 62870
Total Common Shares Outstanding 1248 1247 1254 1254
Total Preferred Shares Outstanding - - - -
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai Apr 27, 2021 7:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job GILD. bullish move forward
Ashraf Elgendy
Ashraf Elgendy Mar 07, 2021 13:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
RM RM
RM RM Mar 01, 2021 21:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up Again
Ken Laing
Ken Laing Oct 23, 2020 18:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to load up before the big rise coming next week
Iggy Maldon
Iggy Maldon Jul 30, 2020 20:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Classic pump n’ dump. What a shambles
RM RM
RM RM May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will reach above 95
Chili Daug
Chili Daug May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when? hahah
SAGAR AGARWAL
SAGAR AGARWAL May 15, 2020 14:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good time to accumulate.
Khizer Malik
Khizer Malik May 14, 2020 11:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
Willy Chin
Willy Chin Apr 23, 2020 18:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
High chance to be trading above 90, good long stock
Viktor Veselý
Viktor Veselý Apr 12, 2020 7:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email